Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                    Movies   Aviation   Pharma   About Us   Feedback   Links
ABORTION PILL DEATHS IN US
 


 

Death of women raises alarm on abortion pill’s safety

Use of abortion pill Mifeprex along with misoprostol results in six deaths, doctors worried about safety.

BY OUR PHARMA CORRESPONDENT
April 4, 2006

In the wake of reports that two more women had died after taking abortion pill, the US doctors started doubting the safety of abortion pills.

Mifeprex, also known as RU-486, induces a miscarriage, in association with another drug, misoprostol that generally occurs within two weeks. To some women, this process seems more natural than surgery, and the expulsion of the fetus often takes place at home, which some also prefer. However, doctors prefer surgery to pill abortion as many of them consider the method rather "lousy’’.

The number of women who have died in the United States after taking Mifeprex has now reached six, according to reports received by the Food and Drug Administration; another has died in Canada. 

Mifeprex has been used in more than 560,000 abortions in the US, so the reported risk of death is a bit more than one in 100,000. Some deaths may have gone unreported, meaning the real risk may be even higher. 

By contrast, the reported risk of death associated with surgical abortion is one in a million, according to studies — one-tenth as high.

Pill-based abortions are also 5 to 10 times as likely to fail as surgical ones, and those that do fail require a follow-up surgical procedure in women whose pregnancies by then may have advanced significantly.

Also, women who undergo medical abortions suffer an increase in complications, some doctors say. A 1999 study of 377 women found that those who took the pills suffered significantly higher levels of pain, nausea, vomiting and worrisome bleeding than those who underwent surgical abortions. 

Probing the deaths, the F.D.A. officials said that there was neither a definitive link between the infections and RU-486 nor any concrete evidence that the drug increased the risk of infection beyond that found in women who underwent surgical abortions, suffered natural miscarriages or gave birth.

More related stories from Pharma


Healing prayers no cure for the ill, says study

Pulmonary hypertension drug PulmoLAR in human trial

Pharma markets in China, Korea, Mexico, Russia & Turkey gather pace

Pfizer’s anxiety drug Lyrica gets EU nod

Asymmetrical breasts: A presage to cancer?

Dream to eradicate polio still far off

GlaxoSmithKline loses fluticasone case

Able files recast plan with bankruptcy court

Ranbaxy in pact with Zenotech on cancer drugs

Lupin and Aspen to form JV on TB drugs

Blood cancer drug Ceflatonin gets orphan drug status

Bangladesh to set up API park; to export drugs worth Tk 8.50 cr to Burma

Wockhard Limited: A profile
Cipla Ltd company profile

 

 

 

Latest Stories in Pharma

 Vertex commences phase II studies for Aurora kinase inhibitor VX-680

GlaxoSmithKline starts H5N1 avian flu vaccine trials in Germany, Belgium

Novartis acquires rights for two drug leads

Serono plans major acquisitions

Samaritan to sell Amphocil in Greece

HIV infection cases fall in South India

Flu drug: Erimos, NC State University seek patent for EM-1421

HollisterStier inks pact with Prism Pharma on cardiovascular drug PM101

Erbitux approved for head and neck cancer in Europe

EPIX Pharmaceuticals merges with Predix

Avanir's involuntary emotional expression disorder (IEED) drug Neurodex gets priority review

 Death of women raises alarm on abortion pill’s safety

Prestwick gets approvable letter for Xenazine for treatment of chorea with HD

Nexavar - Kidney cancer drug gets Swiss nod

Anti-rejection drug Prograf approved in US

 

Latest Stories in Pharma

Archived Pharma stories

 

Latest updates    Contact Us - Feedback    About Us